Trial Profile

A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Adefovir; Entecavir; Granulocyte macrophage colony stimulating factor
Indications Hepatitis B
Focus Therapeutic Use
Acronyms ANCHOR

08 Feb 2022 Results (n=80) assessing the biomarkers associated with a durable functional cure and to dissect the potential immunological mechanisms, published in the Journal of Hepatology.
29 Aug 2020 Interim results (n=249) presented at The International Liver Congress 2020
24 Oct 2017 Interim results (n=101) assessing virological supression, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com